Alaunos Therapeutics, Inc.
TCRT
$1.89
-$0.175-8.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -50.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -50.00% | |||
| Cost of Revenue | -46.69% | 503.49% | |||
| Gross Profit | 46.38% | -483.33% | |||
| SG&A Expenses | 14.32% | -11.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.03% | 44.14% | |||
| Operating Income | 4.85% | -44.64% | |||
| Income Before Tax | 2.05% | -44.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.05% | -44.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.05% | -44.61% | |||
| EBIT | 4.85% | -44.64% | |||
| EBITDA | 4.86% | -44.67% | |||
| EPS Basic | 6.43% | -44.61% | |||
| Normalized Basic EPS | 6.45% | -44.61% | |||
| EPS Diluted | 6.43% | -44.61% | |||
| Normalized Diluted EPS | 6.45% | -44.61% | |||
| Average Basic Shares Outstanding | 4.68% | 0.00% | |||
| Average Diluted Shares Outstanding | 4.68% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||